# Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

> **NCT05089084** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 75 (actual)

## Conditions studied

- Familial Chylomicronemia

## Interventions

- **DRUG:** Plozasiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05089084
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-14
- **Primary completion:** 2024-04-29
- **Final completion:** 2026-04
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089084, "Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05089084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*